Table 4 SNPs and overall grade ≥ 3 toxicity associations in GC patients treated with platinum/fluoropyrimidines-based chemotherapy
Gen SNP ID | Model | Genotypes | Control (n = 61) n (%) | Case (n = 32) n (%) | OR [95% CI] | p-value |
|---|---|---|---|---|---|---|
ERCC2 | Dom | T/T | 39 (63.9%) | 16 (50%) | Ref. | 0.20 |
rs13181 T > G | T/G-G/G | 22 (36.1%) | 16 (50%) | 1.77 (0.74–4.22) |  | |
DPYD | – | T/T | 57 (95%) | 28 (87.5%) | Ref |  |
rs2297595 T > C | C/T | 3 (5%) | 4 (12.5%) | 2.71 (0.57–12.97) | 0.21 | |
DPYD | Dom | T/T | 22 (36.7%) | 18 (56.2%) | Ref | Â |
rs1801159 T > C | C/T-C/C | 38 (63.3%) | 14 (43.8%) | 0.45 (0.19–1.08) | 0.071 | |
DPYD | Dom | A/A | 40 (66.7%) | 10 (32.3%) | Ref | Â |
rs1801265 A > G | A/G-G/G | 20 (33.3%) | 21 (67.7%) | 4.20 (1.70–10.95) | 0.002 | |
GSTP1 | Dom | A/A | 22 (36.1%) | 14 (43.8%) | Â | Â |
rs1695 A > G |  | A/G-G/G | 39 (63.9%) | 18 (56.3%) | 0.72 (0.30–1.74) | 0.47 |